NYSE:NVO
Novo Nordisk A/S Stock News
$127.29
+2.70 (+2.17%)
At Close: May 07, 2024
4 Reasons to Add Novo Nordisk (NVO) Stock to Your Portfolio
02:18pm, Monday, 11'th Apr 2022
Novo Nordisk's (NVO) portfolio of marketed drugs are driving year over year growth. The company has one of the broadest diabetes portfolios in the industry.
Nullagine Gold Production Update
02:27pm, Thursday, 07'th Apr 2022 GlobeNewswire Inc.
VANCOUVER, British Columbia, April 07, 2022 (GLOBE NEWSWIRE) -- Novo Resources Corp. (“Novo” or the “Company”) (TSX: NVO, NVO.WT & NVO.WT.A) (OTCQX: NSRPF) provides a Q1 2022 operational upd
2 Drugmakers Set for Explosive Revenue This Decade
10:00am, Sunday, 03'rd Apr 2022 The Motley Fool
They are selling much-needed products.
Novo Reports 2021 Financial Results
12:26am, Friday, 01'st Apr 2022 GlobeNewswire Inc.
VANCOUVER, British Columbia, March 31, 2022 (GLOBE NEWSWIRE) -- Novo Resources Corp. (“Novo” or the “Company”) (TSX: NVO, NVO.WT & NVO.WT.A) (OTCQX: NSRPF) is pleased to announce its financi
The Zacks Analyst Blog Highlights Apple, The Procter & Gamble, Chevron, Novo Nordisk and Canadian Natural Resources Limited
02:41pm, Wednesday, 30'th Mar 2022 Zacks Investment Research
Apple, The Procter & Gamble, Chevron, Novo Nordisk and Canadian Natural Resources Limited have been included in this Analyst Blog.
Top Analyst Reports for Apple, P & G, Chevron & Others
07:55pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), The Procter & Gamble Company (PG), and Chevron Corporation (CVX).
Novo Nordisk (NVO) Gets FDA Nod for Ozempic's Label Expansion
03:28pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
The FDA approves Novo Nordisk's (NVO) Ozempic 2.0 mg dose for the treatment of adults with type II diabetes. The medicine is now approved at 0.5 mg, 1.0 mg and 2.0 mg doses for the given indication.
Novo Nordisk (NVO) Gets FDA Nod for Ozempic's Label Expansion
12:48pm, Tuesday, 29'th Mar 2022
The FDA approves Novo Nordisk's (NVO) Ozempic 2.0 mg dose for the treatment of adults with type II diabetes. The medicine is now approved at 0.5 mg, 1.0 mg and 2.0 mg doses for the given indication.
Why Novo Nordisk Shares Are Trading Higher Today
09:38am, Tuesday, 29'th Mar 2022
The FDA has approved Novo Nordisk A/S's (NYSE: NVO) 2.0 mg dose of Ozempic (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analog for type 2 diabetes. Ozempic
Novo Nordisk's Ozempic drug gets FDA OK for 2 mg dose to treat Type-2 Diabetes
04:12am, Tuesday, 29'th Mar 2022
By Dominic Chopping
1 Green Flag for Eli Lilly Investors in 2022 -- and 1 Red Flag
03:00pm, Friday, 25'th Mar 2022 The Motley Fool
Does the upside outweigh the downside for this pharma giant?
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
03:00pm, Thursday, 24'th Mar 2022 The Motley Fool
These two companies offer products that are always in demand, regardless of economic conditions.
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
11:00am, Thursday, 24'th Mar 2022
These two companies offer products that are always in demand, regardless of economic conditions.
This group of stocks is flagging a rebound, and that's good news for the S&P 500, says technical analyst
01:05pm, Tuesday, 22'nd Mar 2022 MarketWatch
Where is the market going after last week's rally? Our call of the day from MKM's chief strategist is looking at healthy signals from the healthcare sector.
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022
03:07pm, Wednesday, 16'th Mar 2022 Benzinga
Upgrades
Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to year-ago quarter EPS of
